Tirzepatide grew out of a simple research question in incretin biology: if activating one incretin receptor influences metabolic signaling, what happens when a single molecule engages two at once?
From single to dual agonism
Earlier research established GLP-1 receptor agonists — the class that includes semaglutide — as a major area of study. Investigators then explored adding GIP (glucose-dependent insulinotropic polypeptide) activity, since GIP is the other principal incretin. Tirzepatide emerged as a synthetic peptide engineered to bind both receptors, becoming a reference molecule for the incretin research class.
Why it became a benchmark
Its dual profile made tirzepatide a natural comparator in studies against single-receptor agonists, and later against the triple agonist retatrutide. For the biology behind it, see the incretin receptors explained.
Product page: Tirzepatide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.